Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating mirikizumab for moderate-to-severe plaque psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2020-09-25